Role of adjunctive treatment strategies in COVID-19 and a review of international and national clini

• 作 者: Xin-Ni Xu Yew Kwang Ong De Yun Wang
• 机 构: Department of Otolaryngology-Head and Neck Surgery, National University Hospital System, Singapore,
• 出 处: 军事医学研究（英文）
• 发表日期: 2020年2期
• 关键词: COVID-19 Adjunctive treatment Chloroquine Lopinavir-ritonavir Remdesivir Cortico

The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could t the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by intational and national organizations in healthcare.